Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Combining venetoclax with CPX-351 for AML

Tapan Kadia • 3 Dec 2020
ASH 2020
Leukemia CPX-351 Cytarabine Daunorubicin Venetoclax

Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the findings of an investigation (NCT03629171) into combining CPX-351 and venetoclax to treat acute myeloid leukemia (AML). CPX-352 is a dual-drug made up of daunorubicin and cytarabine. The combination was tolerable and efficacy data is encouraging, particularly in the venetoclax-naïve subgroup. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Tapan Kadia

Updates on established therapies in AML
19:03
Updates on established therapies in AML
Jessica Altman et al. • 20 Sep 2025
CLIA (cladribine, idarubicin, and cytarabine) plus venetoclax in newly diagnosed AML
2:35
CLIA (cladribine, idarubicin, and cytarabine) plus venetoclax in newly diagnosed AML
Tapan Kadia • 8 Dec 2024
Cladribine with low-dose cytarabine & venetoclax alternating with azacitidine & venetoclax in AML
2:47
Cladribine with low-dose cytarabine & venetoclax alternating with azacitidine & venetoclax in AML
Tapan Kadia • 8 Dec 2024
Pegfilgrastim improves outcomes of intensive chemotherapy plus venetoclax in newly diagnosed AML
2:34
Pegfilgrastim improves outcomes of intensive chemotherapy plus venetoclax in newly diagnosed AML
Tapan Kadia • 8 Dec 2024

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals